-->
Newborn eye imaging systems market was valued at US$ 1.86 billion in 2024 and is projected to hit the market valuation of US$ 3.09 billion by 2033 at a CAGR of 5.81% during the forecast period 2025–2033.
The multiple myeloma market is set for steady growth, with revenue expected to rise from USD 22.6 billion in 2024 to USD 30.3 billion by 2033, reflecting a compound annual growth rate (CAGR) of 3.3%.
Japan hemophilia treatment market was valued at US$ 556.69 million in 2024 and is projected to hit the market valuation of US$ 937.37 million by 2033 at a CAGR of 6.16% during the forecast period 2025–2033.
Japan regenerative medicine and cell & gene therapy cold chain logistics market was valued at US$ 60.07 million in 2024 and is projected to hit the market valuation of US$ 209.84 million by 2033 at a CAGR of 15.86% during the forecast period 2025–2033.
Analytical instrumentation market was valued at US$ 55.50 billion in 2024 and is projected to hit the market valuation of US$ 101.09 billion by 2033 at a CAGR of 6.89% during the forecast period 2025–2033.
Generic pharmaceuticals contract manufacturing market was valued at US$ 79.15 billion in 2024 and is projected to hit the market valuation of US$ 135.43 billion by 2033 at a CAGR of 6.15% during the forecast period 2025–2033.
DNA nanotechnology market was valued at US$ 4.77 billion in 2024 and is projected to hit the market valuation of US$ 25.57 billion by 2033 at a CAGR of 21.50% during the forecast period 2025–2033.
Clinical data management system market was valued at US$ 4.08 billion in 2024 and is projected to hit the market valuation of US$ 10.35 billion by 2033 at a CAGR of 10.9% during the forecast period 2025–2033.
Cardiovascular health supplements market was valued at US$ 10.27 billion in 2024 and is projected to hit the market valuation of US$ 22.12 billion by 2033 at a CAGR of 8.9% during the forecast period 2025–2033.